

**SPECIAL ARTICLE**

# Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†</sup>

G. Argilés<sup>1</sup>, J. Tabernero<sup>2</sup>, R. Labianca<sup>3</sup>, D. Hochhauser<sup>4</sup>, R. Salazar<sup>5</sup>, T. Iveson<sup>6</sup>, P. Laurent-Puig<sup>7,8,9</sup>, P. Quirke<sup>10</sup>, T. Yoshino<sup>11</sup>, J. Taieb<sup>7,8,9,12</sup>, E. Martinelli<sup>13</sup> & D. Arnold<sup>14</sup>, on behalf of the ESMO Guidelines Committee\*

<sup>1</sup>Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; <sup>2</sup>Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain; <sup>3</sup>Department Oncology, Ospedale Papa Giovanni XXIII, Bergamo, Italy; <sup>4</sup>UCL Cancer Institute, London, UK; <sup>5</sup>Department of Medical Oncology, Catalan Institute of Oncology, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, Barcelona, Spain; <sup>6</sup>University Hospital Southampton, NHS Foundation Trust, Southampton, UK; <sup>7</sup>Assistance Publique-Hôpitaux de Paris AP-HP Paris Centre, Paris; <sup>8</sup>Paris Cancer Institute CARPEM, Centre de Recherche des Cordeliers, Paris Sorbonne University, Paris University, Paris; <sup>9</sup>INSERM, CNRS, Paris, France; <sup>10</sup>Pathology and Data Analytics, School of Medicine, University of Leeds, Leeds, UK; <sup>11</sup>National Cancer Centre Hospital East, Kashiwa, Japan; <sup>12</sup>Department of Gastroenterology and GI Oncology, Georges Pompidou European Hospital, Paris Descartes University, Paris, France; <sup>13</sup>Università degli Studi della Campania Luigi Vanvitelli, Department of Precision Medicine, Naples, Italy; <sup>14</sup>Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany



Available online 20 July 2020

**Key words:** localised colon, Clinical Practice Guidelines, diagnosis, treatment and follow-up

## INTRODUCTION

### *Incidence and epidemiology*

Colorectal cancer (CRC) is the third most common tumour in men and the second in women, accounting for 10% of all tumour types worldwide. Incidence is 25% higher in males and differs greatly between countries. With more than 600 000 deaths estimated each year, CRC is the fourth most common cancer-related cause of death globally.<sup>1,2</sup> The growing incidence in some countries reflects a modification in lifestyle and its consequences related with 'Westernisation' such as obesity, physical inactivity, alcohol consumption, high red meat intake and cigarette smoking.<sup>3</sup> Some data suggest a putative role in colon cancer carcinogenesis for factors that cause imbalances in gut microbiota.<sup>4,5</sup>

The mortality rate in the European Union is 15–20 out of 100 000 in males and 9–14 out of 100 000 in females and has decreased over time, particularly in females. In affected European individuals, 5-year survival ranges from 28.5% to 57% in men and from 30.9% to 60% in women, with a pooled estimation in 23 countries of 46.8% in men and 48.4% in women.<sup>6</sup>

The risk of developing colon cancer depends on factors which can be classified into lifestyle or behavioural

characteristics and genetically determined factors. Screening tests are modulated according to the individual probability of developing CRC.<sup>7–9</sup> Age is considered the major unchangeable risk factor for sporadic colon cancer: nearly 70% of patients are >65 years of age and this disease is rare before the age of 40 years, even though data from Western registries show an increased incidence in the 40–44-year age group.<sup>10</sup>

Individuals with any of the following are considered at high risk of colon cancer and must be actively screened and in case of inherited syndromes, also referred for genetic counselling (see ESMO guidelines for hereditary gastrointestinal cancer<sup>11</sup>):

- a medical history of adenoma, colon cancer, inflammatory bowel disease (Crohn's disease and ulcerative colitis);
- significant family history of CRC or adenoma;
- an inherited cancer syndrome (2%–5% of all CRC), such as familial adenomatous polyposis coli and its variants (1%), Lynch-associated syndromes (hereditary non-polyposis colon cancer) (2%–4%), Turcot, Peutz–Jeghers and *MUTYH*-associated polyposis syndrome.

## SCREENING PRINCIPLES

CRC arises following progression of normal mucosa to an invasive tumour, passing through different intermediate stages of premalignant and invasive malignant lesions; this stepwise process facilitates cancer prevention and early diagnosis when the tumour is still at an early stage and curable, through screening programmes. For average-risk

\*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, 6900 Lugano, Switzerland  
E-mail: [clinicalguidelines@esmo.org](mailto:clinicalguidelines@esmo.org) (ESMO Guidelines Committee).

<sup>†</sup>Approved by the ESMO Guidelines Committee: April 2002, last update May 2020. This publication supersedes the previously published version—*Ann Oncol*. 2013;24(suppl 6):vi64-vi72.

0923-7534/© 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.

populations, European and American evidence-based guidelines for quality assurance in CRC screening<sup>12,13</sup> should be followed.

## Recommendations

### Colonoscopic tests

- Colonoscopic techniques, despite being invasive, have the advantage of being both diagnostic and therapeutic.
- A complete colonoscopy is the recommended method for CRC screening in average-risk men and women based on higher sensitivity and specificity when compared with other tests<sup>14</sup> [II, B]. The optimal age range for testing is 50–74 years [V, C] with an optimal repetition interval for a negative test of 10 years [III, C].
- Flexible sigmoidoscopy (FS) carried out every 5–10 years may be an alternative for those who refuse colonoscopy [II, B]. The combination of this method with a yearly faecal occult blood test (FOBT) (see below) is recommended to reduce the risk of a right colon tumour [III, B].
- Other invasive tests including capsule colonoscopy are not recommended for screening [IV].

### Non-invasive tests

- Non-colonoscopy tests are recommended in average-risk men and women from the age of 50 not already taking part in colonoscopic screening programmes. The optimal frequency of testing is every year and no later than every three years [I, B]. A colonoscopy must be carried out at the earliest convenience when the test results are positive [I, A].
- Among the available tests, faecal immunochemical testing (FIT) appears to be superior to high-resolution guaiac FOBT with respect to the detection rate and positive predictive value for adenomas and cancer [III]. Other novel methods including DNA-based or tests using other markers (e.g. M2-PK) lack formal comparisons of their performance, and integration with other assays needs to be monitored.

Screening for high-risk populations is covered in the ESMO guidelines for hereditary gastrointestinal cancer.<sup>11</sup>

## DIAGNOSIS

### Symptoms and signs

Colon cancer arises from the mucosa of the bowel, growing both into the lumen and the bowel wall, and/or spreading to adjacent organs. Symptoms are associated with relatively large tumours and/or advanced disease stages and may not be specific for colon cancer. Alterations in bowel habit, general or localised abdominal pain, weight loss without other specific causes, weakness, iron deficiency and anaemia are the most common symptoms and depend on the location and stage of the primary tumour.<sup>15,16</sup> Colon cancer can occur with multiple or synchronous lesions

(3.6%)<sup>17</sup> with identical or different histological patterns and stages of development. Metachronous primary tumours arise in up to 3% of cases during the 5 years after surgery, and the incidence increases up to 9% after several decades in long-term survivors, justifying long-term surveillance of the colon in patients who have already experienced colon cancer.<sup>18</sup>

### Diagnostic work-up

A complete work-up should be carried out to achieve an accurate histological diagnosis of the primary tumour, assess the baseline characteristics of the patient and determine the extent of the disease (see Table 1).

**Diagnosis of the primary tumour.** In the absence of a bowel obstruction or massive haemorrhage, which may constitute indications of an urgent tumour resection, a total colonoscopy is recommended for diagnostic confirmation of colon cancer [I, A]. There are many advantages of endoscopy including determination and marking of the exact tumour location and biopsy of the lesion and detection and removal of (further) synchronous precancerous or cancerous lesions. Combining the limited left-sided colonoscopy with computed tomography (CT), colonoscopy is an alternative if full colonoscopy is not feasible [I, A].<sup>19</sup> In cases where complete colonic exploration cannot be carried out before surgery, a complete colonoscopy should be carried out within 3–6 months [IV, B].

### Assessment of patient baseline status and characteristics.

After colonic tumour diagnosis, clinical examination and laboratory tests must be carried out to provide a correct assessment of patient status and characteristics before deciding the definitive treatment approach [II, A].

Besides a comprehensive physical examination<sup>20</sup> [IV], blood tests including complete blood count, coagulation, liver and kidney functions tests as well as albumin can

**Table 1. Diagnostic work-up for localised CRC**

Local assessment	LoE, GoR
Complete colonoscopy	I, A
<b>Imaging work-up</b>	
CT scan:	
• Lung	V
• Abdominal	I, B
• Pelvic	I, B
CT colonography (when complete colonoscopy is not feasible)	I, A
MRI abdominal (to clarify ambiguous lesions or define pT4b)	II, A
<b>Laboratory work-up</b>	
Complete blood count	II, A
Coagulation	II, A
Liver function panel	II, A
Kidney function panel	II, A
Albumin	III, A
CEA	III, A

CEA, carcinoembryonic antigen; CRC, colorectal cancer; CT, computed tomography; GoR, grade of recommendation; LoE, level of evidence; MRI, magnetic resonance imaging.

provide relevant clinical information regarding the patient's baseline conditions and the existence of cancer-related complications [II, A].

In addition, serum levels of carcinoembryonic antigen (CEA), although not sufficient for colon cancer diagnosis themselves in the absence of a confirmatory tumour biopsy (because of low specificity and sensitivity), should be evaluated before surgery and monitored during the follow-up period to help the early detection of metastatic disease [III, A].<sup>21–23</sup> In addition, CEA level determination after colon cancer diagnosis is of particular importance since baseline levels add information in defining prognosis; a post-operative serum CEA level >5 ng/ml (or even >2.35) suggests a worse outcome.<sup>21</sup>

**Assessment of distant tumour extension.** Preoperative assessment of tumour extension is required to determine whether the patient should be referred for primary tumour resection or, in the presence of unresectable distant metastases, systemic therapy. Approximately 20% of newly diagnosed colon cancers have synchronous metastases, the most frequently involved organ being the liver (17%), followed by peritoneum (5%), lung (5%) and lymph nodes (3%).<sup>24</sup>

CT of the thoracic, abdominal and pelvic cavities with intravenous (i.v.) contrast administration is the preferred radiological method for the evaluation of the presence of distant metastases of CRC [II, B]. This test allows evaluation of locoregional tumour extension and its complications (e.g. obstruction, perforation, fistula, abscess).<sup>25</sup> Nevertheless, CT scanning may fail to detect peritoneal metastases, where sensitivity is relatively poor and depends on implant localisation and size.<sup>26,27</sup>

Contrast-enhanced magnetic resonance imaging (MRI) permits better definition of the soft tissues. It constitutes the reference test when it is necessary to evaluate the relationship of locally advanced tumours with surrounding structures or in defining ambiguous liver lesions previously detected by CT scan [II, A].<sup>28</sup> Likewise, MRI can substitute for CT scanning in patients with iodine-contrast allergies or chronic renal insufficiency where the glomerular filtration rate is <30 ml/min [II, A].<sup>29–31</sup>

Fluorodeoxyglucose positron emission tomography (FDG-PET), with or without integrated CT (positron emission tomography/CT), does not add significant information to the CT scans on preoperative staging of CRC and is not recommended for routine use in staging of localised CRC beyond assisting in interpretation of ambiguous findings [II, A].<sup>32,33</sup>

### Recommendations

- In the absence of indications for urgent tumour resection, a total colonoscopy is recommended for diagnostic confirmation of colon cancer and to rule out synchronous tumours. Combining the limited left-sided colonoscopy with CT colonoscopy is an alternative if full colonoscopy is not possible [I, A].

- When not carried out before or during the surgical procedure, a complete colonoscopy should be carried out within 3–6 months following tumour resection [IV, B].
- Comprehensive physical examination and laboratory tests including full blood counts, biochemistry and serum CEA levels must be carried out before decisions on the definitive treatment approach [III, A].
- CT of the thoracic, abdominal and pelvic cavities with i.v. contrast administration is the preferred radiological method for the evaluation of the extent of CRC [II, B].
- Contrast-enhanced MRI constitutes the reference test for evaluation of the relationship of locally advanced tumours with surrounding structures or in defining ambiguous liver lesions [II, A].

## MANAGEMENT OF LOCALISED COLONIC TUMOURS

### Treatment of adenocarcinomas presenting in adenomas

Complete *en bloc* endoscopic resection should be carried out whenever the morphological structure of the polyp permits.<sup>34</sup> Endoscopic resection is sufficient for hyperplastic or adenomatous polyps and non-invasive (pTis, i.e. intra-epithelial or intramucosal) adenocarcinomas<sup>35</sup> (see Figure 1). For (pT1) invasive carcinomas, the management is determined by the polyp morphology and the presence of histological features associated with adverse outcome<sup>36</sup>:

- lymphatic or venous invasion;
- grade 3 differentiation;
- significant (grade >1) tumour budding.<sup>37</sup>

For a pedunculated polyp with a pT1 carcinoma confined to the head, neck and stalk (Haggitt 1–3) endoscopic resection with proper follow-up is enough even with the presence of submucosal invasion, provided that no other unfavourable factors are present [IV, B].<sup>38</sup> However, the presence of any unfavourable factor in a sessile or flat polyp (Paris classification) with a pT1 carcinoma mandates surgical resection in patients with average operative risk [IV, B].<sup>39</sup> The goal of surgical resection is complete lesion resection, including lymph node removal for optimal risk assessment [IV, B]. In contrast, finding positive resection margins (<1 mm) constitutes only a risk for local recurrence and can be managed by excision repetition or local surveillance.<sup>39</sup>

When surgery is not possible due to significant comorbidities, surveillance colonoscopy within 6 months after polyp removal is recommended, as well as close oncological follow-up including CT scan to detect lymph node recurrences [IV, B].<sup>38,39</sup>

### Management of locally infiltrative colon cancers

Infiltrative colon cancers cannot be resected by colonoscopy and require surgery, with the goal of wide resection of the involved bowel segment and its lymphatic drainage [I, A]. The extent of the colonic resection is determined by the blood supply and distribution of regional lymph nodes. The resection should include a segment of colon of at least 5 cm




Figure 1. Diagnostic algorithm for localised colon cancer.

on either side of the tumour, but wider margins are often included due to the mandatory ligation of the arterial blood supply [IV, B]. *En bloc* colonic and mesentery resection is recommended in order to clearly define stage II versus stage III and to identify and eradicate potential lymph node metastases; at least 12 lymph nodes should be resected when feasible [IV, B].<sup>40</sup> Likewise, *en bloc* resection of adjacent organ-invaded portions must be carried out in case of pT4b<sup>41</sup> [I, B].

During the procedure, a complete assessment of the peritoneal cavity and ovaries should be carried out to investigate for possible metastasis<sup>41</sup> [I, C]. (See ESMO guidelines for metastatic colorectal cancer for the management of patients with removed metastases<sup>42</sup>).

Laparoscopic colectomy can be safely carried out for colon cancer when technical expertise is available in the absence of contraindications in view of reduced morbidity, improved tolerance and similar oncological outcomes [I, C].<sup>43,44</sup>

Obstructive CRCs can be treated in one or two stages. Two-stage procedures can include colostomy followed by colonic resection or, in the case of bowel perforation, Hartmann's procedure followed by colostomy closure and anastomosis. One-stage procedures are preferred when carried out by experienced teams; subtotal colectomy and

ileorectal anastomosis or segmental resection after intra-operative colonic lavage are alternatives in selected cases [III]. Colonic stenting<sup>45,46</sup> can be used in expert centres as a bridge to elective surgery, especially in patients with higher rates of postoperative complication after emergency surgery [ $>70$  years old and/or American Society of Anesthesiologists (ASA)  $>II$ ] [II].

### Recommendations

- *En bloc* endoscopic resection of the polyp is sufficient for non-invasive (pTis, i.e. intraepithelial or intramucosal) adenocarcinomas [IV, B].
- The presence of invasive carcinoma (pT1) in a polyp requires a thorough review with the pathologist and surgeon. High-risk features mandating surgical resection with lymphadenectomy include lymphatic or venous invasion, grade 3 differentiation, significant (grade  $>1$ ) and tumour budding [IV, B].
- Laparoscopic colectomy can be safely carried out for colon cancer when technical expertise is available in the absence of contraindications, in view of reduced morbidity, improved tolerance and similar oncological outcomes [I, C].

- Obstructive CRCs can be treated in one- or two-stage procedures, as indicated [III, B].

### **PATHOLOGICAL REPORT**

Pathological reporting should be carried out at the time of surgery to precisely define nodal spread of disease and extension of the tumour through the bowel wall and on to adjacent structures, as well as to assess biopsies when a suspicion of liver or peritoneal metastases has been identified by the surgeon. The standard assessment should include<sup>47</sup>:

- morphological description of the specimen;
- surgical procedure carried out;
- definition of tumour site and size;
- presence or absence of macroscopic tumour perforation;
- histological type and grade;
- extension of tumour into the bowel wall and adjacent organs (T stage);
- distance of cancer from resected margins (proximal, distal and radial);
- presence or absence of tumour deposits;
- lymphovascular and/or perineural invasion;
- presence of tumour budding<sup>37</sup>;
- site and number of removed regional lymph nodes and their possible infiltration by cancer cells (N stage);
- involvement of other organs (e.g. peritoneum) if submitted either removed or biopsied (M stage);
- mismatch repair (MMR)/microsatellite instability (MSI) status of the tumour.

The pathological stage must be reported according to the Union for International Cancer Control (UICC) tumour, node, metastasis (TNM) classification, 8th edition<sup>48</sup> (see [supplementary Table S1](https://doi.org/10.1016/j.annonc.2020.06.022), available at <https://doi.org/10.1016/j.annonc.2020.06.022>).

### **Recommendation**

- A standard surgical/pathological report should include specimen description and surgical procedure, tumour site and size, macroscopic tumour perforation, histological type and grade, extension into the bowel wall and adjacent organs, distance of cancer from resected margins (proximal, distal and radial), presence or absence of tumour deposits, lymphovascular and/or perineural invasion, tumour budding, site and number of removed and involved regional lymph nodes, MMR/MSI status and involvement of other organs [IV, A].

### **RISK ASSESSMENT**

Definitive decisions regarding adjuvant treatment indication can only be made after discussing in detail the risk/benefit ratios of available options with the patient. To this end, the risk of tumour recurrence must be integrated with expected

benefits and complications from the given adjuvant treatment (see [Figure 2](#)).

### **Assessment of recurrence risk and expected benefits from adjuvant therapy**

The assessment of risk of recurrence is important in deciding when to recommend systemic adjuvant treatment with the aim of reducing risk of relapse and death. The risk of relapse after colon cancer resection is estimated by integrating the clinicopathological features of the tumour with the molecular marker MMR/MSI status.<sup>49</sup>

TNM staging remains the most relevant histological criteria for risk assessment after surgery of colon cancer. Reported 5-year survival rates after surgical resection alone are 99% for stage I, 68%–83% for stage II and 45%–65% for stage III disease.<sup>48</sup>

In addition, for intermediate stage II, further parameters need consideration to refine the evaluation of risk given the observed variability on prognosis [III]<sup>49</sup>:

Major prognostic parameters for stage II risk assessment [II]<sup>48–50</sup>:

- Lymph nodes sampling <12;
- pT4 stage including perforation;

Minor prognostic parameters for stage II risk assessment<sup>49</sup> [II]:

- High grade tumour;
- Vascular invasion;
- Lymphatic invasion;
- Perineural invasion;
- Tumour presentation with obstruction;
- High preoperative CEA levels.

In general, it has been established that adjuvant systemic therapy decreases the risk of death by an absolute 3%–5% in high-risk stage II colon cancer with single-agent 5-fluorouracil (5-FU) and by 10%–15% in stage III disease with fluoropyrimidines alone, with a further 4%–5% improvement with oxaliplatin-containing combinations [I, A].

MSI/MMR status is the most validated prognostic molecular marker used in deciding adjuvant therapy next to clinical prognostic factors.

Deficient DNA MMR status can be identified by immunohistochemistry detecting loss of MMR protein expression (MLH1, MSH2, MSH6 or PMS2) or by polymerase chain reaction (PCR) assays of MSI status (microsatellite mutations). Determining MSI/MMR status in localised colon cancer patients has two objectives: to characterise the prognosis and prediction of adjuvant benefit and determine potential genetic predisposition.

MSI/MMR status determination is important to rule out Lynch syndrome. The presence of MSH2 and/or MSH6 loss by IHC indicates suspicion of Lynch syndrome, while MLH1 and PMS2 loss needs to be investigated further by determining *BRAF* mutation or hypermethylation of the




Figure 2. Factors to guide adjuvant decision making.

promoter region of *hMLH1*. The identification of either of these alterations suggests with high probability the presence of an *MLH1* gene somatic acquired alteration rather than Lynch syndrome.<sup>11</sup> Besides its implications for Lynch syndrome diagnosis, MSI/MMR status defines, in localised colon cancer, a subgroup of patients with a better prognosis and less expected benefit from chemotherapy.<sup>51–55</sup> In particular, MSI/MMR may be useful to identify a small (10%–15%) subset of stage II patients who are at a very low risk of recurrence and in whom the benefits of fluoropyrimidines have not been demonstrated and thus adjuvant chemotherapy should not be indicated [I, A].<sup>51–55</sup>

Nomograms have been developed as tools to standardise decision making in the adjuvant setting; however, their use is not widely implemented.<sup>56</sup>

#### Assessment of risk of complications from adjuvant treatment

Administration of an adjuvant treatment should only be done by experienced sites, with a good knowledge of side-effects and (necessary) dose reduction schedules. Despite the proven benefit for patients with stage III and II disease, the (relative) counterindications have to be considered: e.g. Eastern Cooperative Oncology Group (ECOG) performance status >2, uncontrolled infection, severe liver and renal dysfunction and heart failure [New York Heart Association (NYHA) III and IV]. Furthermore, other life-prognosis determining comorbidities have to be taken into account.

Dihydropyrimidine dehydrogenase (DPD) is the main enzyme involved in fluoropyrimidine metabolism. Approximately 3%–5% of patients have deficiencies of DPD function due to genetic polymorphisms leading to increased fluoropyrimidine toxicity, that can be lethal.<sup>57</sup> Based on the recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency

(EMA) dated 13 March 2020, testing for DPD insufficiency should be conducted before initiating fluoropyrimidine-based chemotherapy [III, A]. There are two main ways to assess DPD functionality: through genotyping the *DPYD* gene or through phenotyping DPD function.

Genotyping identifies pathologic polymorphisms in the *DPYD* gene, mainly *DPYD*\*2A, c.1679T>G, c.2846A>T or c.1236G>A.<sup>56</sup> In the presence of a heterozygous polymorphism, the fluoropyrimidine dose should be reduced by 50%, while with homozygous polymorphisms, fluoropyrimidines should not be used due to the high risk of complications [III, A], according to a Dutch cohort observational trial.<sup>57</sup> Phenotyping allows assessment of DPD functionality by measuring the uracilemia in blood.<sup>58–61</sup> For levels >16 ng/ml, the dose should be reduced by 50% and for levels >150 ng/ml, fluoropyrimidines are contraindicated [III, A].<sup>57</sup> In this situation, raltitrexed may be an option for those patients with high risk of recurrence [V].<sup>62</sup>

Age is another criterion for risk assessment in the adjuvant setting although it remains controversial. Analyses from a Canadian database ( $N = 2801$ ) in Ontario indicate that patients in stage III disease between the age of 70 and 79 years received adjuvant treatment in 68% and for patients >80 years in 24%.<sup>63</sup> In this retrospective analysis, all age groups benefited about the same level. However, the indication for an adjuvant treatment had to be associated with the Charlson Comorbidity Index, ensuring that only ‘fit’ elderly patients receive an adjuvant treatment. However, all generalisations from clinical randomised trials are difficult to do, since patients >75 years are underrepresented and/or excluded.

On the other hand, the addition of oxaliplatin to any fluoropyrimidine should be used with caution in this population.<sup>63,64</sup> A pooled analysis from 4 randomised trials, NSABP-C08, XELOXA, X-ACT and AVANT, has shown that in all age groups, treatment with oxaliplatin can be considered, if clinically indicated.<sup>65</sup> The hazard ratio (HR) for overall survival (OS) with oxaliplatin was 0.78 for patients of 70 years or older; however, younger patients experienced a greater benefit (HR 0.62) and had a significantly lower rate of toxicity. Similar data were demonstrated in the NO16968 trial (XELOX versus bolus 5FU/FA: HR for OS in patients 70 years or older: 0.91 (0.66–1.26) versus 0.80 at younger patients).<sup>64</sup> A similar existing but reduced benefit also occurred in the analysis of the ACCENT database.<sup>66</sup>

#### Use of personalised medicine in localised colon cancer/ biomarkers for risk assessment

Besides MSI status, other genetic markers, e.g. *RAS* and *BRAF* mutations are not recommended for the routine assessment of risk of recurrence in non-metastatic patients, based on their lack of utility in the adjuvant decision-making process.<sup>67</sup> However, other biomarkers such as gene signatures, Immunoscore and postoperative circulating tumour DNA (ctDNA) have demonstrated some benefit in determining the risk of recurrence and can be considered in addition to pathological features and MSI status to further tailor the adjuvant decision making in difficult cases.<sup>68–71</sup>

Gene signatures have emerged as potential candidates for prognostic stratification in locoregional disease. At the time of writing, only Oncotype DX<sup>68</sup> and GeneFxCOLON<sup>69</sup> have been validated in multivariate analysis of independent prospective randomised cohorts of stage II colon cancer with formalin-fixed paraffin-embedded (FFPE) tumour samples. Although routine clinical utility is not warranted due to lack of predictive value for chemotherapy benefit and the small prognostic differentiation margins between high, intermediate and low scores, their use might be considered in complementing clinicopathological information on intermediate-risk stage II scenarios: i.e. to treat T3 N0 classified as high risk by the signature, or for avoiding chemotherapy in T4 N0 classified as low risk by the signature [II, C].

Immunoscore has been recently validated in a large prospective cohort of >2500 patients TNM stage I–III.<sup>70</sup> Immunoscore was a strong predictor for time to recurrence, OS and disease-free survival (DFS) (all  $P < 0.0001$ ), independently of patient age, sex, MSI and other existing prognostic factors. Immunoscore had the highest relative contribution to the risk of all clinical parameters, including the UICC TNM classification system.<sup>70</sup> Therefore, Immunoscore could help refine the prognosis of early colon cancer patients in conjunction with the TNM scoring [III, C]. However, its role in predicting chemotherapy benefit is uncertain and firm evidence of its prognostic role in a stage-II-only dataset is currently lacking.

Finally, ctDNA monitoring, also known as liquid biopsy, is a promising tool under investigation to identify patients with high risk of recurrence after primary tumour resection. Indeed, ctDNA detection after stage II colon cancer resection has been demonstrated to provide direct evidence of residual disease and to identify patients at very high risk of recurrence.<sup>71</sup> The results of ongoing trials investigating the role of ctDNA as a tool to stratify patient's risk of relapse and to determine allocation to different adjuvant therapeutic strategies must be awaited before this is accepted in routine practice. The CIRCULATE-IDEA and de Circulatie-Europa collaborations seek to pool the data coming from the main national trials exploring ctDNA follow-up in the adjuvant setting. The results of this initiative will probably set the final role of ctDNA in the adjuvant decision-making process.

### Recommendations

- Adjuvant therapy options should be fully discussed with the patient, taking into consideration tumour risk of recurrence, expected benefit from chemotherapy and risk of complications.
- The risk of relapse after a colon cancer resection should be assessed by integrating the TNM staging, MMR/MSI status and number of lymph nodes sampled ( $\pm 12$ ) [III, A].
- Other additional clinicopathological features such as the histological subtype and grading, lymphatic or venous or perineural invasion, lymphoid inflammatory response, involvement of resection margins and serum CEA should

be taken into consideration for refining the risk assessment on stage II tumours [III, A].

- Patient age alone has no predictive value for or against the indication to an adjuvant treatment and must be considered in the context of (potential) benefit, underlying risk for relapse, life expectancy in relation to (biological) age and comorbidities. However, it can be generalised that benefits of treatment with both, fluoropyrimidines alone and plus/minus oxaliplatin, seem to be more limited with a higher likelihood for toxicity in older patients.
- MSI/MMR status is the only validated molecular marker used in adjuvant decision making and should be determined in stage II CRC. In stage III, usage of MMR status is limited to detect and identify Lynch syndrome [IV, A].
- DPD genotyping or phenotyping is strongly recommended before initiating fluoropyrimidine-based adjuvant therapy according to regulatory bodies [III, A].
- Gene expression signatures are not recommended for routine practice due to lack of predictive value for chemotherapy benefit; however, clinicians and patients may consider their use to complement clinicopathological information in intermediate-risk stage II scenarios although their role in predicting chemotherapy benefit is uncertain [II, C].
- Immunoscore could be considered to refine the prognosis of early colon cancer patients used in conjunction with the TNM scoring and thus adjust the chemotherapy decision-making process in stage II and even in low-risk stage III patients [III, C], although its role in predicting chemotherapy benefit is uncertain.

## TREATMENT OPTIONS

### Stage III disease

The current standard of care for adjuvant therapy in stage III colon cancer is a combination of fluoropyrimidine and oxaliplatin. The benefit of these combinations over fluoropyrimidine monotherapy, the prior standard of care, has been demonstrated in three landmark trials: MOSAIC, NSABP C-07 and XELOXA. All showed significant improvement in DFS compared with fluoropyrimidine as single agent.<sup>72–74</sup> The MOSAIC study used an infusional fluoropyrimidine regimen in both arms [leucovorin/5-fluorouracil (LV5FU2) and leucovorin/5-fluorouracil/oxaliplatin (FOLFOX)], the NSABP C-07 study used a bolus fluoropyrimidine regimen in both arms [Roswell Park and leucovorin/5-fluorouracil/irinotecan/oxaliplatin (FLOX)], whereas the XELOXA study used a bolus fluoropyrimidine regimen (Mayo Clinic or Roswell Park) compared with capecitabine plus oxaliplatin (CAPOX). The MOSAIC and NSABP C-07 studies included both stage II and stage III colon cancer, while the XELOXA study included only stage III colon cancer.

Although the chemotherapy regimens in the three studies were different, the addition of oxaliplatin resulted in a similar reduction in risk of recurrence in all three

studies (23% in MOSAIC and 20% in NSABP C-07 and XELOXA). With longer follow-up, all three trials showed improved OS from the addition of oxaliplatin with a risk reduction of death of 16% in MOSAIC, 12% in NSABP C-07 and 17% in XELOXA.<sup>65,72,75</sup> However, a significant improvement in OS was only shown to be significant for stage III colon cancer.

FOLFOX and CAPOX remain the current standard of care. As the FLOX regimen results in increased incidence of diarrhoea compared with FOLFOX or CAPOX, FLOX is not currently recommended in clinical practice; in addition, irinotecan, cetuximab and bevacizumab have not demonstrated clinical activity in the localised setting and therefore they should never be used as adjuvant treatment in this setting [I, E].<sup>76–80</sup>

**IDEA collaboration, choice of regimen and treatment duration of adjuvant treatment.** The major cumulative toxicity from a fluoropyrimidine/oxaliplatin doublet is sensory peripheral neuropathy. Worldwide, there have been six studies investigating whether 3 months of adjuvant chemotherapy is non-inferior to 6 months of treatment, with the aim of thereby diminishing the incidence of neuropathy and healthcare costs. These six trials have been examined prospectively by an international collaboration and published as the IDEA study.<sup>81</sup> In this pooled analysis, 12 834 patients with stage III colon cancer were randomised to receive either 3 months or 6 months of a fluoropyrimidine/oxaliplatin doublet (either FOLFOX or CAPOX); the choice of regimen was mainly the clinician's choice and not randomised. The 3-year DFS rates were similar (overall: 74.6% and 75.5% for 3 months and 6 months, respectively) but the pre-defined non-inferiority margin, accepting a 12% decrease as the upper limit of inferiority to be ruled out, was not confirmed in the overall study population [HR 1.07; 95% confidence interval (CI) 1.00–1.15].

However, sensory peripheral neuropathy grade 2 or worse was significantly reduced from 34% with 6 months of treatment to 11% with 3 months of treatment.

In the IDEA study, the treatment duration depends on the choice of regimen. For patients receiving CAPOX, 3 months treatment was non-inferior with 3-year DFS of 75.9% and 74.8% for 3 and 6 months, respectively, whereas for FOLFOX, 3 months treatment was inferior with 3-year DFS of 73.6% and 76.0% for 3 and 6 months, respectively. Therefore, non-inferiority of the shorter regimen was seen for CAPOX (HR 0.95; 95% CI 0.85–1.06) but not for FOLFOX (HR 1.16; 95% CI 1.06–1.26).

Thus, both CAPOX for 3 months and FOLFOX for 6 months can be recommended as adjuvant chemotherapy regimens for stage III colon cancer [I, A]. It is important to mention that CAPOX and FOLFOX assignment in the IDEA trials was not randomised, precluding any formal comparison between the two regimens.

CAPOX mitigates the need for central venous access and decreased neurotoxicity rates if 3 months is adequate but is associated with more diarrhoea and hand-foot syndrome than FOLFOX; thus, it may be relatively contraindicated if a

patient has an ileostomy and in cases of renal insufficiency. FOLFOX has higher reported neutropaenia rates. Immediate oxaliplatin cessation following occurrence of grade >1 neuropathy is recommended in all cases (whatever the regimen and treatment duration) to avoid long-lasting symptomatic neurotoxicity that will impair the patient's quality of life.


**Definition of risk groups in stage III.** The IDEA study also conducted an exploratory analysis based on risk subgroups. In the lower-risk subgroup (defined as patients with T1, T2 or T3 with N1 disease), 3 months of adjuvant therapy appeared to be sufficient, when CAPOX was chosen [II, B]. In the higher-risk group (patients with T4 or N2 or both), 6 months of treatment may be necessary, especially when FOLFOX is the chosen regimen, but also with CAPOX, which missed the non-inferiority margin on this subgroup [II, B].

However, the panel believes that the establishment of stage III risk subgroups should be used with caution, since this was a *post-hoc* analysis on the IDEA collaboration: T4 versus T1–3 and N2 versus N1 subgroup analyses were pre-specified in the protocol but their combination in high-versus low-risk subgroups was not, and moreover, its interaction test was not significant ( $P = 0.11$ ). Thus, the panel agrees that the established high- versus low-risk subgroups in stage III based on IDEA should have level of evidence [V] (see Figure 3 for adjuvant treatment recommendations in stage III).

### Stage II disease

As already discussed, there are major and minor clinicopathological factors that impact on the risk of relapse on stage II colon cancer. The presence of major factors including pT4 stage or <12 lymph nodes assessed confers increased risk of recurrence, while the presence of other additional risk factors is less significantly associated with risk of relapse.<sup>48–50</sup> While follow-up is an option for low-risk stage II patients, chemotherapy is recommended for intermediate- and high-risk patients [I, B].

Although the de Gramont is the only regimen that has demonstrated efficacy in the setting [I, B], capecitabine is an option, especially with contraindications for insertion of a central line [V]. It is also felt by the panel members that patients with high risk, patients with pT4 and/or <12 lymph nodes or accumulation of several intermediate risk factors, might be considered for the addition of oxaliplatin therapy based on a trend to an increased benefit, although this did not achieve statistical significance in the stage II high-risk subgroup analysis of the MOSAIC trial [I, B].<sup>72</sup> For this high-risk population, the IDEA trial explored the optimal duration of the oxaliplatin-based adjuvant treatment, finding identical results to those reported for stage III patients, a non-proven non-inferiority for 3 months of treatment and there was a proven non-inferiority of CAPOX and inferiority of FOLFOX for 3 months when compared with 6 months of FOLFOX,<sup>82</sup> with all the limitations of these *post hoc* analyses as stated before. The presence of MSI/MMR in



**Figure 3. Recommendations for adjuvant treatment of stage III colon cancer.**

CAPOX, capecitabine plus oxaliplatin; FOLFOX, leucovorin/fluorouracil/oxaliplatin; MCBS, ESMO-Magnitude of Clinical Benefit Scale; MSI, microsatellite instability; MSS, microsatellite stability.

localised disease confers better prognosis and less benefit to adjuvant therapy so chemotherapy should be indicated with caution and always in combination with oxaliplatin<sup>51–55</sup> (see Figure 4 for integration of clinicopathological and molecular factors with therapeutic recommendations).

Lifestyle factors are likely to have an important impact on survival following adjuvant chemotherapy in either stage II or III patients, as reported for physical activity and nut consumption.<sup>83,84</sup> In addition, aspirin reduces the risk of polyp formation and may also improve survival after adjuvant chemotherapy in PI3K-mutated colon cancer patients (approximately 20% of all patients).<sup>85</sup> The ADD-ASPIRIN and ASPIK randomised studies are aiming to answer this question definitively.


#### Timing of adjuvant chemotherapy

Delay between surgery and the beginning of adjuvant chemotherapy is a matter of debate. In view of the evidence, it is important to commence adjuvant chemotherapy as soon as possible after surgery and ideally not later than 8 weeks [II, B]. A meta-analysis of 14 studies showed that a

delay of >8 weeks in starting adjuvant chemotherapy is associated with a higher relative risk of death (HR 1.20; 95% CI 1.15–1.26,  $P = 0.001$ ).<sup>86</sup> This observation has been confirmed by other groups.<sup>87,88</sup> However, population-based studies have shown that adjuvant chemotherapy might still provide some benefit, even with delays up to 5–6 months,<sup>89,90</sup> but it seems that the benefit of adjuvant chemotherapy is minimal or completely lost if treatment is started >6 months after surgery.

#### Recommendations

- Combinations of fluoropyrimidines, either 5-FU or capecitabine, and oxaliplatin constitute the bases for stage III colon cancer adjuvant treatment [I, A; European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) v.1.1 score: B].
- The length of oxaliplatin-based adjuvant treatment of stage III colon cancer based on the IDEA data may be tailored to 3 or 6 months for CAPOX [I, A] or 6 months for FOLFOX [I, A] also taking into consideration



**Figure 4. Recommendations for adjuvant treatment of stage II colon cancer.**

CAPOX, capecitabine plus oxaliplatin; CEA, carcinoembryonic antigen; FOLFOX, leucovorin/fluorouracil/oxaliplatin; MSI, microsatellite instability; MSS, microsatellite stability.

<sup>a</sup> For pT4 MSI: pT4 is a major risk factor but adjuvant chemotherapy benefit in the presence of MSI is uncertain.

pathological risk characteristics, patient comorbidity and risk assessment.

- Further adaptation of the treatment according to risk subgroups: 3 months for CAPOX (T1–3 N1 disease), 6 months for CAPOX (T4 or N2 disease) or 6 months for FOLFOX (T1–3 N1 or T4 or N2 disease) based on IDEA collaboration should be made with caution, since this was based on a *post-hoc* analysis, non-significant for interaction [V].
- For patients not fit for or not tolerating oxaliplatin, either capecitabine or LV5FU2 (de Gramont) infusion is acceptable adjuvant regimens for a 6-month duration [I, A].

- For patients with low-risk stage II colon cancer, follow-up is recommended [I, A].
- For patients with intermediate risk (non-MMR/MSI + any risk factor except pT4 or <12 lymph nodes assessed), 6 months of fluoropyrimidines should be recommended [I, B].
- Patients with high-risk stage II (pT4 or <12 lymph nodes or multiple intermediate risk factors, regardless of MSI) may be considered for the addition of oxaliplatin [I, C].
- Patients with high-risk stage II colon cancer may be considered for 3 months of CAPOX, as the IDEA-pooled analysis showed non-inferiority of 3 months of CAPOX

and inferiority of 3 months of FOLFOX when compared with 6 months of FOLFOX, with all the limitations of post-hoc analyses [II, B].

- It is important to start adjuvant chemotherapy as soon as possible after surgery and ideally not later than 8 weeks [I, A].

**FOLLOW-UP AND LONG-TERM IMPLICATIONS**

**Follow-up**

Overall, between 30% and 50% of all patients treated for localised colon cancer will eventually relapse and die of the disease.<sup>91,92</sup> The main goal of follow-up protocols is detecting relapse on an early basis, thereby maximising patient survival in the metastatic setting. Systematic reviews have shown disparate results regarding the use of intensive follow-up as a tool to increase OS.<sup>93,94</sup> However, it has been shown that there is an advance in the detection of recurrences [II, B] with intensive follow-up.<sup>94</sup> Detection of isolated local recurrences was increased in the intensive group (15% compared with 9%, with risk ratio 1.61 and *P* = 0.011), along with a small, non-significant increase in the detection of hepatic metastases.<sup>94</sup> However, heterogeneity of the studies included in these meta-analyses does not allow precise assessment of algorithms for optimal surveillance in clinical practice. Only trials including clinical assessment, CEA testing and/or liver imaging achieved significant improvements in survival, though all studies considering liver imaging also included blood CEA monitoring.<sup>95</sup>

On one hand, CT scan including optimal liver assessment has been shown to be more sensitive than ultrasonography (0.67 compared with 0.43) for liver relapse follow-up and, in addition, can detect chest recurrences. On the other hand, liver MRI may be an alternative when a CT scan has shown confusing liver lesions.<sup>96</sup>

Regarding the timing and duration of follow-up, protocols need to be sensitive to the patterns of relapse of colon cancer. Among recurring patients, 80% of relapses occur during the first 3 years and an additional 15% between the 3rd and 5th year, which supports a more intensive follow-up during the first 3 years and a stop after 5 years.<sup>91,96</sup>


In addition to CEA testing and CT scans, colonoscopies should also be included in the follow-up since metachronous primary cancer can be detected with an incidence of 0.7% within the first 2 years after curative surgery.<sup>97</sup> However, there is no indication for intensive endoscopic follow-up. If a colon without tumour or adenoma is observed 1 year after resection, colonoscopy should be carried out after 3–5 years<sup>97</sup> (see Figure 5 for colon cancer follow-up after curative resection).

**Long-term implications/survivorship care plans**

CRC survivors represent the third largest group of long-term cancer survivors in Western countries, ~11% of this population. For this group, additional post-therapeutic follow-up interventions have demonstrated to improve patient outcomes.<sup>98</sup> In this setting, the primary practitioner should have a significant role in collaborating with the oncological teams.<sup>99,100</sup>

Major elements in survivorship care are as follows:

- Prevention of recurrent and new cancer (classic end point of follow-up).
- Intervention for cancer sequelae and their treatment (rehabilitation).
- Assessment of medical and psychological late effects (modern end point of follow-up).



**Figure 5. Recommendations for follow-up after curative resection.** CEA, carcinoembryonic antigen; CT, computed tomography; mCRC, metastatic colorectal cancer.

- Health promotion (lifestyle promotion, comorbidity prevention, etc.).

Most long-term survivors of CRC report good quality of life following treatment, but several problems are still observed.<sup>101</sup> A significant proportion of patients have persistent bowel dysfunction. It is important to refer for dietary counselling and suggest use of over-the-counter medications (e.g. fibre laxatives, stool softeners, antidiarrheals). Colostomies and ileostomies represent also a source of physiological distress and disturbances at the level of social functioning. Patients should be encouraged to take part in ostomy management programmes and psychological distress management programmes must be recommended in case of discomfort with their body changes.

Colon cancer survivors experience higher rates of sexual distress and psychological depression.<sup>101</sup> Assessment of distress should be considered, but evidence on the effectiveness of psychosocial interventions among survivors of CRC is limited. Patients should be encouraged to maintain a healthy lifestyle including exercise, quitting smoking, avoidance of excessive alcohol intake and adoption of a healthy diet rich in vegetables, fruit and berries adapted to the remaining gastrointestinal function.<sup>102</sup>

### Recommendations

- Intensive follow-up allows earlier detection of relapses in patients at risk [II, B].
- History and physical examination and CEA level determination are advised every 3–6 months for 3 years and every 6–12 months at years 4 and 5 after surgery [II, B].
- Colonoscopy must be carried out at year 1 and every 3–5 years thereafter, looking for metachronous adenomas and cancers [III, B].
- CT scan of chest and abdomen every 6–12 months for the first 3 years can be considered in patients who are at higher risk of recurrence according to the TNM classification [II, B].
- Other laboratory and radiological examinations are of unproven benefit and must be restricted to patients with suspicious symptoms [V, C].
- Long-term follow-up, rehabilitation and survivorship care programmes should be implemented, aiming at detection of recurrent or new cancers, assessment and management of late and psychosocial effects and implementation of health promotion measures [III, A].

### METHODOLOGY

These Clinical Practice Guidelines were developed in accordance with the ESMO standard operating procedures for Clinical Practice Guidelines development (<http://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology>). The relevant literature has been selected by the expert authors. An ESMO-MCBS table with ESMO-MCBS scores is included in [supplementary Table S2](https://doi.org/10.1016/j.annonc.2020.06.022), available at <https://doi.org/10.1016/j.annonc.2020.06.022>.<sup>103</sup> ESMO-MCBS v.1.1 was

used to calculate scores for new therapies/indications approved by the EMA since 1 January 2016 (<https://www.esmo.org/Guidelines/ESMO-MCBS>). The scores have been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee. Levels of evidence and grades of recommendation have been applied using the system shown in [supplementary Table S3](https://doi.org/10.1016/j.annonc.2020.06.022), available at <https://doi.org/10.1016/j.annonc.2020.06.022>.<sup>104</sup> Statements without grading were considered justified standard clinical practice by the experts and the ESMO Faculty. This manuscript has been subjected to an anonymous peer review process.

### ACKNOWLEDGEMENTS

The ESMO Guidelines Committee would like to thank the ESMO Faculty and other experts who provided critical reviews of these ESMO Clinical Practice Guidelines.

### FUNDING

No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds (no grant number).

### DISCLOSURE

GA has reported that he has acted as a consultant or speaker for Amgen, Roche, Merck, Sanofi, Servier, Merck Sharp & Dohme and Bayer. JTab has reported consultancy or speaker roles for Amgen, Roche, Merck, Celgene, Lilly, Sanofi, Sirtex, Pierre Fabre, Merck Sharp & Dohme and Servier. TI has reported honoraria for advisory boards from Amgen, Bayer, Bristol-Myers Squibb, Celgene, Pierre-Fabre, Roche and Servier. DH has received research funding from Merck Serono. JTai has reported personal financial interest from scientific consultancy roles for Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Inc., Genmab A/S, Halozyme, Imugene Limited, Inflection Biosciences Limited, Ipsen, Kura Oncology, Lilly, Merck Sharp & Dohme, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, F. Hoffmann-La Roche Ltd, Sanofi, Seagen, Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS and Roche Diagnostics and institutional financial support for clinical trials or contracted research for Agendia BV, Amgen SA, Debiopharm International SA, Janssen-Cilag SA, Mologen AG, Novartis Farmaceutica SA, PharmaMar, Roche Farma SA, Laboratorios Servier SL and Symphogen A/S. RL has reported leadership role for GISCAD. RS has reported advisory board/speaker for Pfizer, Novartis, Amgen, Merck and Merck Sharpe & Dohme, advisory board for VCN-Biosciences, Agendia, Guardant Health, Roche Diagnostics, Ferrer, Ipsen, Roche Pharma and Lilly, speaker role for AstraZeneca and Celgene, leadership role for and stocks from Sace Medhealth, grants/research support from Roche Diagnostics, Novartis Farmaceutica, VCN Biosciences, Merck KGaA, Roche Farma and Mologen. PLP has

reported advisory board/speaker for Amgen, AstraZeneca, Biocartis, Boehringer Ingelheim, Merck, Merck Sharp & Dohme, Bristol-Myers Squibb, Roche and Sanofi. PQ has received research funding from Roche, Amgen, Halio, Intragen, Genomic Health, GeneFirst, Adlai Nordlyte and Leica and acted as a consultant or speaker for Roche, Bayer, Amgen and Merck Serono and is a National Institute for Health Senior Investigator. TY has reported research funding from Novartis Pharma KK, Merck Sharp & Dohme KK, Sumitomo Dainippon Pharma Co., Ltd, Chugai Pharmaceutical Co., Ltd, Sanofi KK, Daiichi Sankyo Co., Ltd, Parexel International Inc., ONO Pharmaceutical Co., Ltd and GlaxoSmithKline KK. EM has received honoraria for lecture and advisory boards from Roche, Amgen, Servier, Astra Zeneca, Bayer, Merck-Serono, Pierre Fabre and Sanofi, grant support from AIRC and speaker support from ESMO. DA has acted as a consultant or speaker for Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Roche, Merck Serono, Sanofi, Pierre Fabre, Merck Sharp & Dohme, Boston Scientific, Terumo and Servier.

## REFERENCES

1. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. *Gut*. 2017;66:683-691.
2. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet*. 2015;385:977-1010.
3. Kerr J, Anderson C, Lippman SM. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. *Lancet Oncol*. 2017;18:e457-e471.
4. Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of fusobacterium persistence and antibiotic response in colorectal cancer. *Science*. 2017;358:1443-1448.
5. Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, et al. Mutational signature in colorectal cancer caused by genotoxic pks(+) *E. coli*. *Nature*. 2020;580:269-273.
6. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. *Cancer Epidemiol Biomarkers Prev*. 2016;25:16-27.
7. Lauby-Secretan B, Vilahur N, Bianchini F, et al. The IARC perspective on colorectal cancer screening. *N Engl J Med*. 2018;378:1734-1740.
8. Ryan NAJ, Morris J, Green K, et al. Association of mismatch repair mutation with age at cancer onset in Lynch syndrome: implications for stratified surveillance strategies. *JAMA Oncol*. 2017;3:1702-1706.
9. Inadomi JM. Screening for colorectal neoplasia. *N Engl J Med*. 2017;376:149-156.
10. Davis DM, Marcet JE, Frattini JC, et al. Is it time to lower the recommended screening age for colorectal cancer? *J Am Coll Surg*. 2011;213:352-361.
11. Stjepanovic N, Moreira L, Carneiro F, et al. Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30:1558-1571.
12. Atkin WS, Valori R, Kuipers EJ, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition — colonoscopic surveillance following adenoma removal. *Endoscopy*. 2012;44:E151-E163.
13. Lin JS, Piper MA, Perdue LA, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US preventive services task force. *JAMA*. 2016;315:2576-2594.
14. Bretthauer M, Kaminski MF, Løberg M, et al. Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial population-based colonoscopy screening for colorectal cancer. *JAMA Intern Med*. 2016;176:894-902.
15. McDermott FT, Hughes ESR, Pihl E, et al. Prognosis in relation to symptom duration in colon cancer. *Br J Surg*. 1981;68:846-849.
16. Ford AC, Veldhuyzen van Zanten SJ, Rodgers CC, et al. Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. *Gut*. 2008;57:1545-1553.
17. Lam A, Carmichael R, Buettner PG, et al. Clinicopathological significance of synchronous carcinoma in colorectal cancer. *Am J Surg*. 2011;202:39-44.
18. Fajobi O, Yiu C, Sen-Gupta SB, Boulos PB. Metachronous colorectal cancers. *Br J Surg*. 1998;85:897-901.
19. Halligan S, Wooldrage K, Dadswell E, et al. Computed tomographic colonography versus barium enema for diagnosis of colorectal cancer or large polyps in symptomatic patients (SIGGAR): a multicentre randomised trial. *Lancet*. 2013;381:1185-1193.
20. Hamilton W, Round A, Sharp D, Peters TJ. Clinical features of colorectal cancer before diagnosis: a population-based case-control study. *Br J Cancer*. 2005;93:399-405.
21. Konishi T, Shimada Y, Hsu M, et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. *JAMA Oncol*. 2018;4(3):309-315.
22. Duffy MJ, van Dalen A, Haglund C, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. *Eur J Cancer*. 2003;39:718-727.
23. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. *J Clin Oncol*. 2006;24:531305327.
24. van der Geest LG, Lam-Boer J, Koopman M, et al. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. *Clin Exp Metastasis*. 2015;32:457-465.
25. Horton KM, Abrams RA, Fishman EK. Spiral CT of colon cancer: imaging features and role in management. *Radiographics*. 2000;20:419-430.
26. Nerad E, Lahaye MJ, Maas M, et al. Diagnostic accuracy of CT for local staging of colon cancer: a systematic review and meta-analysis. *AJR Am J Roentgenol*. 2016;207:984-995.
27. Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. *Ann Surg Oncol*. 2009;16:327-333.
28. Sahani DV, Bajwa MA, Andrabi Y, et al. Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma. *Ann Surg*. 2014;259:861-872.
29. ACR Committee on Drugs and Contrast Media. Manual on Contrast Media Version 10.3. American College of Radiology; 2018. Available at [https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast\\_Media.pdf](https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf). Accessed March 4, 2020.
30. van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury — Part 1: definition, clinical features, incidence, role of contrast medium and risk factors: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. *Eur Radiol*. 2018;28:2845-2855.
31. van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. *Eur Radiol*. 2018;28:2856-2869.
32. Furukawa H, Ikuma H, Seki A, et al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. *Gut*. 2006;55:1007-1011.
33. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. *Radiology*. 2010;257:674-684.
34. Ferlitsch M, Moss A, Hassan C, et al. Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. *Endoscopy*. 2017;49:270-297.
35. Aarons CB, Shanmugan S, Bleier JI. Management of malignant colon polyps: current status and controversies. *World J Gastroenterol*. 2014;20:16178-16183.

36. Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. *Gastroenterology*. 1985;89:328-336.
37. Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. *Mod Pathol*. 2017;30:1299-1311.
38. Backes Y, Elias SG, Groen JN, et al. Histologic factors associated with need for surgery in patients with pedunculated T1 colorectal carcinomas. *Gastroenterology*. 2018;154:1647-1659.
39. Bujanda L, Cosme A, Gil I, Arenas-Mirave JI. Malignant colorectal polyps. *World J Gastroenterol*. 2010;16:3103-3111.
40. Voyer TEL, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analysed: a secondary survey of intergroup trial INT-0089. *J Clin Oncol*. 2003;21:2912-2919.
41. Xynos E, Gouvas N, Triantopoulou C, et al. Clinical practice guidelines for the surgical management of colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO. *Ann Gastroenterol*. 2016;29:3-17.
42. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2014;25(suppl 3):iii1-iii9.
43. Nelson H, Sargent DJ, Wieand HS, et al. A comparison of laparoscopically assisted and open colectomy for colon cancer. *N Engl J Med*. 2004;350:2050-2059.
44. Hewett PJ, Allardyce RA, Bagshaw PF, et al. Short-term outcomes of the Australasian randomized clinical study comparing laparoscopic and conventional open surgical treatments for colon cancer: the ALCCaS trial. *Ann Surg*. 2008;248:728-738.
45. Ribeiro IB, Bernardo WM, Martins BDC, et al. Colonic stent versus emergency surgery as treatment of malignant colonic obstruction in the palliative setting: a systematic review and meta-analysis [published correction appears in *Endosc Int Open* 2018;6:C1]. *Endosc Int Open*. 2018;6:E558-E567.
46. van Hooft JE, Veld JV, Arnold D, et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline — Update 2020. *Endoscopy*. 2020;52:389-407.
47. Washington MK, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. *Arch Pathol Lab Med*. 2009;133:1539-1551.
48. Brierley JD, Gospodarowicz MK, Wittekind C, eds. *TNM Classification of Malignant Tumours*. 8th edition. Oxford: John Wiley & Sons, Inc.; 2016.
49. Roth AD, Delorenzi M, Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. *J Natl Cancer Inst*. 2012;104:1635-1646.
50. Wells KO, Hawkins AT, Krishnamurthy DM, et al. Omission of adjuvant chemotherapy is associated with increased mortality in patients with T3N0 colon cancer with inadequate lymph node harvest. *Dis Colon Rectum*. 2017;60:15-21.
51. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *N Engl J Med*. 2003;349:247-257.
52. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. *J Clin Oncol*. 2010;28:3219-3226.
53. Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. *J Natl Cancer Inst*. 2011;103:863-875.
54. Tejpar S, Saridaki Z, Delorenzi M, et al. Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle. *J Natl Cancer Inst*. 2011;103:841-844.
55. Kim JE, Hong YS, Kim HJ, et al. Defective mismatch repair status was not associated with DFS and OS in stage II colon cancer treated with adjuvant chemotherapy. *Ann Surg Oncol*. 2015;22(Suppl 3):S630-S637.
56. Weiser MR, Landmann RG, Kattan MW, et al. Individualized prediction of colon cancer recurrence using a nomogram. *J Clin Oncol*. 2008;26:380-385.
57. Henricks LM, Lunenburg C, de Man FM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. *Lancet Oncol*. 2018;19:1459-1467.
58. Lloria M-A, Ciccolini J, Thomas F, et al. Dépistage du déficit en dihydropyrimidine déshydrogénase (DPD) et sécurisation des chimiothérapies à base de fluoropyrimidines: mise au point et recommandations nationales du GPCO-Unicancer et du RNPdGx. *Bull Cancer*. 2018;105:397-407.
59. Meulendijks D, Henricks LM, Jacobs BAW, et al. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. *Br J Cancer*. 2017;116(11):1415-1424.
60. Etienne-Grimaldi MC, Boyer JC, Beroud C, et al. New advances in DPYD genotype and risk of severe toxicity under capecitabine. *PLoS One*. 2017;12(5):e0175998.
61. Lloria MA, Masskouri F, Carni P, et al. Intérêts et limites de la recherche du déficit en dihydropyrimidine déshydrogénase dans le suivi des patients traités par fluoropyrimidines: résultats de deux enquêtes nationales de pratiques réalisées auprès des médecins et des biologistes [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]. *Bull Cancer*. 2019;106(9):759-775.
62. Popov I, Carrato A, Sobrero A, et al. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). *Eur J Cancer*. 2008;44:2204-2211.
63. Booth CM, Nanji S, Wei X, et al. Use and effectiveness of adjuvant chemotherapy for stage III colon cancer: a population-based study. *J Natl Compr Canc Netw*. 2016;14:47-56.
64. Haller DG, O'Connell MJ, Cartwright TH, et al. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. *Ann Oncol*. 2015;26:715-724.
65. Schmoll HJ, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. *J Clin Oncol*. 2015;33:3733-3740.
66. McCleary NJ, Meyerhardt JA, Green E, et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. *J Clin Oncol*. 2013;31:2600-2606.
67. Taieb J, Le Malicot K, Shi Q, et al. Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer. *J Natl Cancer Inst*. 2017;109(5):djw272.
68. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. *J Clin Oncol*. 2011;29:4611-4619.
69. Niedzwiecki D, Frankel WL, Venook AP, et al. Association between results of a gene expression signature assay and recurrence-free interval in patients with stage II colon cancer in cancer and leukemia group B 9581 (Alliance). *J Clin Oncol*. 2016;34:3047-3053.
70. Pages F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. *Lancet*. 2018;391:2128-2139.
71. Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. *Sci Transl Med*. 2016;8:346ra392.
72. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J Clin Oncol*. 2009;27:3109-3116.

73. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. *J Clin Oncol*. 2007;25:2198-2204.
74. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. *J Clin Oncol*. 2011;29:1465-1471.
75. Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. *J Clin Oncol*. 2011;29:3768-3774.
76. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. *J Clin Oncol*. 2009;27(19):3117-3125.
77. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. *JAMA*. 2012;307:1383-1393.
78. Taieb J, Tabernero J, Mini E, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. *Lancet Oncol*. 2014;15:862-873.
79. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. *J Clin Oncol*. 2011;29:11-16.
80. de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. *Lancet Oncol*. 2012;13:1225-1233.
81. Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer. *N Engl J Med*. 2018;378:1177-1188.
82. Iveson T, Sobrero AF, Yoshino T, et al. Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colorectal cancer (CC). *J Clin Oncol*. 2019;37(Suppl 15):3501.
83. Meyerhardt JA, Heseltine D, Niedzwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. *J Clin Oncol*. 2006;24:3535-3541.
84. Fadelu T, Zhang S, Niedzwiecki D, et al. Nut consumption and survival in patients with stage III colon cancer: results from CALGB 89803 (Alliance). *J Clin Oncol*. 2018;36:1112-1120.
85. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. *N Engl J Med*. 2012;367:1596-1606.
86. Des Guetz G, Nicolas P, Perret GY, et al. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. *Eur J Cancer*. 2010;46:1049-1055.
87. Hershman D, Hall MJ, Wang X, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. *Cancer*. 2006;107:2581-2588.
88. Gao P, Huang XZ, Song YX, et al. Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study. *BMC Cancer*. 2018;18:234.
89. Kim YW, Choi EH, Kim BR, et al. The impact of delayed commencement of adjuvant chemotherapy (eight or more weeks) on survival in stage II and III colon cancer: a national population-based cohort study. *Oncotarget*. 2017;8:80061-80072.
90. Turner MC, Farrow NE, Rhodin KE, et al. Delay in adjuvant chemotherapy and survival advantage in stage III colon cancer. *J Am Coll Surg*. 2018;226:670-678.
91. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. *J Clin Oncol*. 2009;27:872-877.
92. Seo SI, Lim SB, Yoon YS, et al. Comparison of recurrence patterns between  $\leq 5$  years and  $>5$  years after curative operations in colorectal cancer patients. *J Surg Oncol*. 2013;108:9-13.
93. Wille-Jørgensen P, Syk I, Smedh K, et al. Effect of more vs less frequent follow-up testing on overall and colorectal cancer-specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. *JAMA*. 2018;319:2095-2103.
94. Alhayek-Aí M, López-Calviño B, Pérttega-Díaz S, et al. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. *Ann Oncol*. 2014;26:644-656.
95. Chau I, Allen MJ, Cunningham D, et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. *J Clin Oncol*. 2004;22:1420-1429.
96. Tsikitis VL, Malireddy K, Green EA, et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. *J Clin Oncol*. 2009;27:3671-3676.
97. Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology*. 2006;130:1865-1871.
98. Howell D, Hack TF, Oliver TK, et al. Models of care for post-treatment follow-up of adult cancer survivors: a systematic review and quality appraisal of the evidence. *J Cancer Surviv*. 2012;6:359-371.
99. Grunfeld E, Earle CC. The interface between primary and oncology specialty care: treatment through survivorship. *J Natl Cancer Inst Monogr*. 2010;2010:25-30.
100. Sisler JJ, Taylor-Brown J, Nugent Z, et al. Continuity of care of colorectal cancer survivors at the end of treatment: the oncology-primary care interface. *J Cancer Surviv*. 2012;6:468-475.
101. Schneider EC, Malin JL, Kahn KL, et al. Surviving colorectal cancer: patient-reported symptoms 4 years after diagnosis. *Cancer*. 2007;110:2075-2082.
102. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. *JAMA*. 2007;298:754-764.
103. Cherny NI, Dafni U, Bogaerts J, et al. ESMO-Magnitude of Clinical Benefit Scale Version 1.1. *Ann Oncol*. 2017;28:2340-2366.
104. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. *Clin Infect Dis*. 2001;33:139-144 (Adapted from: Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. *Clin Infect Dis*. 1994;18:421).